Table 1 Baseline characteristics of neoadjuvant Aumolertinib treated patients (n = 51)
Variables | All Patients | Mutant Subtypes, No. (%) | ||
|---|---|---|---|---|
Ex19-Del | Ex21-L858R | P | ||
No. of Patients (%) | 51 | 22 (43.1) | 27 (56.9) | |
Age, years (range) | 0.170 | |||
62.6 (40–76) | 61.1 (47–75) | 64.7 (40–76) | ||
Gender | 0.740 | |||
Male | 23 (45.1) | 10 (45.5) | 11 (40.7) | |
Female | 28 (54.9) | 12 (54.5) | 16 (59.3) | |
ECOG | 0.362 | |||
0 | 30 (58.8) | 11 (50.0) | 17 (63.0) | |
1 | 21 (41.2) | 11 (50.0) | 10 (37.0) | |
Smoking Status | 0.869 | |||
Ever | 16 (31.4) | 15 (68.2) | 19 (70.4) | |
Never | 35 (68.6) | 7 (31.8) | 8 (29.6) | |
PD-L1 Expression | 0.282 | |||
Positive | 12 (23.5) | 7 (31.8) | 5 (18.5) | |
Negative or unknow | 39 (76.5) | 15 (68.2) | 22 (81.5) | |
TLD in CT, mm (range) | 0.055 | |||
50.0 (17–113) | 54.1 (20–92) | 42.9 (17–111) | ||
PT-S in PET-CT | 0.567 | |||
11.7 (3.5–26.8) | 11.2 (3.9–23.4) | 12.0 (3.5–26.8) | ||
N Stage | 0.037 | |||
1 | 11 (21.6) | 6 (27.3) | 5 (18.5) | |
2 | 25 (49.0) | 6 (27.3) | 17 (63.0) | |
3 | 15 (29.4) | 10 (45.4) | 5 (18.5) | |
cTNM Stage | 0.242 | |||
IIIA | 24 (47.1) | 11 (50.0) | 13 (48.1) | |
IIIB | 22 (43.1) | 7 (31.8) | 13 (48.1) | |
IIIC | 5 (9.8) | 4 (18.2) | 1 (3.8) | |
Histological Subtype | 0.096 | |||
Pure LUAD | 46 (90.2) | 18 (81.8) | 26 (96.3) | |
NSCLC containing other subtypes | 5 (9.8) | 4 (18.2) | 1 (3.7) | |
EGFR Mutation | / | |||
Ex19Del | 22 (43.1) | 22 | 0 | |
L858R | 27 (52.9) | 0 | 27 | |
Uncommon | 2 (4.0) | 0 | 0 | |
